Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ExPEC9V vaccine trial for prevention of invasive extraintestinal pathogenic Escherichia coli disease in older adults with prior urinary tract infection
2020-005273-27Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in invasive extraintestinal pathogenic Escherichia coli disease (IED) and urinary tract infection (UTI) comparing ExPEC9V with Placebo (2 arms). Primary endpoint: Primary efficacy endpoints. Started Jun 2021; status: active.
02
Drugs
ExPEC9V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)urinary tract infection (UTI)
Beyond the preview
Go deeper on 2020-005273-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005273-27.